Tirzepatide 5mg

Tirzepatide 5mg

Rated 0 out of 5
(be the first to review)

$75.00

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite

Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists

  • Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
  • Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
  • Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at (−4 °F); after reconstitution, refrigerate at  (35.6–46.4 °F); use within 28 days.
Category:

Description

Tirzepatide is a prescription medication used to treat type 2 diabetes, manage chronic weight loss (in adults with obesity or those overweight with at least one weight-related condition), and treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is the active ingredient in the brand-name drugs Mounjaro (for diabetes) and Zepbound (for weight management and OSA), manufactured by Eli Lilly. 
How It Works
Tirzepatide is a “first-in-class” dual agonist that mimics two natural gut hormones: 
  • Glucose-dependent insulinotropic polypeptide (GIP).
  • Glucagon-like peptide-1 (GLP-1). 
By activating the receptors for both hormones, tirzepatide works in several ways: 
  • It stimulates the pancreas to release more insulin when blood sugar levels are high.
  • It reduces the amount of sugar produced by the liver.
  • It slows down gastric emptying, which helps patients feel fuller for longer periods.
  • It targets areas in the brain that regulate appetite, which can help reduce food cravings and “food noise” (constant thoughts about eating). 
Administration and Dosage
Tirzepatide is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. The dosage typically starts low (2.5 mg) and is gradually increased by a healthcare provider every four weeks based on the patient’s tolerance and response, up to a maximum dose of 15 mg weekly. 

Reviews

There are no reviews yet.

Leave a customer review

Your email address will not be published. Required fields are marked *

Related products

Back To Top